Neuregulin-1 attenuates experimental cerebral malaria (ECM) pathogenesis by regulating ErbB4/AKT/STAT3 signaling. by Liu, Mingli et al.
UC Riverside
UC Riverside Previously Published Works
Title
Neuregulin-1 attenuates experimental cerebral malaria (ECM) pathogenesis by regulating 
ErbB4/AKT/STAT3 signaling.
Permalink
https://escholarship.org/uc/item/94d5n942
Journal
Journal of neuroinflammation, 15(1)
ISSN
1742-2094
Authors
Liu, Mingli
Solomon, Wesley
Cespedes, Juan Carlos
et al.
Publication Date
2018-04-10
DOI
10.1186/s12974-018-1147-z
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH Open Access
Neuregulin-1 attenuates experimental
cerebral malaria (ECM) pathogenesis by
regulating ErbB4/AKT/STAT3 signaling
Mingli Liu1* , Wesley Solomon1, Juan Carlos Cespedes1, Nana O. Wilson2, Byron Ford3 and Jonathan K. Stiles1*
Abstract
Background: Human cerebral malaria (HCM) is a severe form of malaria characterized by sequestration of infected
erythrocytes (IRBCs) in brain microvessels, increased levels of circulating free heme and pro-inflammatory cytokines
and chemokines, brain swelling, vascular dysfunction, coma, and increased mortality. Neuregulin-1β (NRG-1) encoded
by the gene NRG1, is a member of a family of polypeptide growth factors required for normal development of the
nervous system and the heart. Utilizing an experimental cerebral malaria (ECM) model (Plasmodium berghei ANKA in
C57BL/6), we reported that NRG-1 played a cytoprotective role in ECM and that circulating levels were inversely
correlated with ECM severity. Intravenous infusion of NRG-1 reduced ECM mortality in mice by promoting
a robust anti-inflammatory response coupled with reduction in accumulation of IRBCs in microvessels and
reduced tissue damage.
Methods: In the current study, we examined how NRG-1 treatment attenuates pathogenesis and mortality
associated with ECM. We examined whether NRG-1 protects against CXCL10- and heme-induced apoptosis
using human brain microvascular endothelial (hCMEC/D3) cells and M059K neuroglial cells. hCMEC/D3 cells
grown in a monolayer and a co-culture system with 30 μM heme and NRG-1 (100 ng/ml) were used to
examine the role of NRG-1 on blood brain barrier (BBB) integrity. Using the in vivo ECM model, we examined whether the
reduction of mortality was associated with the activation of ErbB4 and AKT and inactivation of STAT3 signaling
pathways. For data analysis, unpaired t test or one-way ANOVA with Dunnett’s or Bonferroni’s post test was applied.
Results: We determined that NRG-1 protects against cell death/apoptosis of human brain microvascular endothelial
cells and neroglial cells, the two major components of BBB. NRG-1 treatment improved heme-induced disruption of
the in vitro BBB model consisting of hCMEC/D3 and human M059K cells. In the ECM murine model, NRG-1 treatment
stimulated ErbB4 phosphorylation (pErbB4) followed by activation of AKT and inactivation of STAT3, which attenuated
ECM mortality.
Conclusions: Our results indicate a potential pathway by which NRG-1 treatment maintains BBB integrity in
vitro, attenuates ECM-induced tissue injury, and reduces mortality. Furthermore, we postulate that
augmenting NRG-1 during ECM therapy may be an effective adjunctive therapy to reduce CNS tissue injury
and potentially increase the effectiveness of current anti-malaria therapy against human cerebral malaria (HCM).
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Background
Human cerebral malaria (HCM) is a severe form of mal-
aria characterized by sequestration of infected erythro-
cytes (IRBCs) in brain microvessels, increased levels of
circulating free heme and pro-inflammatory cytokines and
chemokines, brain swelling, vascular dysfunction, coma,
and increased mortality. The resulting leakiness of the
blood brain barrier (BBB) caused by the decreased cere-
bralvascular integrity allows increased trafficking of toxic
compounds into the brain parenchyma leading to exacerba-
tion of neurological deficits [1, 2]. The BBB is a highly se-
lective semipermeable membrane barrier consisting of
cerebral vascular endothelial cells and astrocytes surround-
ing them. It separates the circulating blood from the brain
and extracellular fluid [3] and protects neural tissues
against various unfavorable compositions and toxins in the
blood. Dysfunctional microvascular endothelial cells or as-
trocytes compromise the integrity of the BBB, a hallmark of
HCM pathogenesis [4, 5]. We have reported that elevation
of circulating CXCL10 and free heme induce apoptosis of
human brain microvascular endothelial cells (hCMEC/D3)
and astroglia/neuroglia (M059K) [6, 7], indicating the im-
portant roles played by circulating CXCL10 and free heme
in mediating experimental cerebral malaria (ECM) and
HCM pathogenesis, BBB integrity, and mortality [8, 9].
The neuregulin family of ligands consist of four mem-
bers, neuregulin 1β (NRG-1), NRG-2, NRG-3, and NRG-
4. While little is known about the biological functions of
NRG-2, NRG-3, and NRG-4 [10], NRG-1 has been
widely studied in stroke [11, 12], cardiovascular diseases
[13, 14], and tumors [15, 16]. NRG-1, a secreted trophic
factor, is encoded by the neuregulin/NRG-1 gene located
on the short arm of chromosome 8 [17, 18]. Alternative
splicing produces at least 15 different NRG-1 isoforms,
which are grouped as types I, II, and III [19, 20]. All four
genes in the NRG-1 family (NRG1–4) share a common
epidermal growth factor (EGF)-like domain. Type I
NRGα and NRGβ isoforms are the predominant iso-
forms expressed in early embryogenesis, whereas types
II and III NRG are not detectable until at mid-gestation
stage [19]. Type III, which is also called sensory and
motor neuron-derived factor (SMDF), is the most dom-
inant type of NRG-1 in the human adult brain, account-
ing for about 73% of total NRG-1 [21, 22]. The ErbB
receptors are a family composed of receptors of ErbB1,
ErbB2, ErbB3, and ErbB4. Any isoform of NRG1 is cap-
able of directly binding and activating ErbB3 and ErbB4
receptors although the biological significance is incom-
pletely understood [19]. The ErbB3 receptor lacks an ac-
tive kinase domain and is unable to form functional
ErbB3 homodimers [23]. ErbB4 undergoes tertiary struc-
tural changes in the juxtaembrane region when it binds
to its ligand NRG-1 and forms functional homodimers
or heterodimers with ErbB1, ErbB2, and ErbB3.
Phosphorylation of the ErbB4 receptor results in the
recruitment of adaptor/effecter molecules [24] and
initiates/activates numerous downstream signaling path-
ways crucial to neuronal development, neuronal migra-
tion, axonal navigation, and synaptic function [25]. We
recently reported that intravenous infusion of NRG-1
significantly reduced mortality associated with ECM by
promoting a robust anti-inflammatory response and re-
ducing accumulation of intra vascular IRBC as well as
tissue damage [26]. In the current study, we explored a
potential molecular mechanism by which NRG-1 regu-
lates downstream pathways to improve/restore the integ-
rity of the BBB and attenuate ECM pathogenesis.
Results
NRG-1 protects against CXCL10- and heme-induced
apoptosis in astrocytes and endothelial cells
We previously reported that mortality associated with
HCM correlates with increased serum CXCL10 levels
and that treatment of both endothelial hCMEC/D3 and
neuroglial M059K cells with CXCL10 at a physiologically
relevant concentration of 0.02 μg/ml in vitro induced
apoptosis [6]. To test the protective effects of NRG-1,
we treated hCMEC/D3 and M059K cells, respectively,
with CXCL10 and NRG-1 ranging from 50 to 250 ng/ml
for 24 h and assayed for apoptosis by TUNEL. NRG-1
attenuated apoptosis of hCMEC/D3 and M059K cells in-
duced by CXCL10 at concentrations as low as 50 ng/ml
and up to a maximum effect at 250 ng/ml (Fig. 1a). As a
follow-up to our first report on the induction of apop-
tosis by heme in human brain microvascular endothelial
cells [7], we next tested whether NRG-1 had anti-
apoptotic effect against hCMEC/D3 and M059K cells
treated with heme. When M059K cells were treated with
heme at the concentrations used for hCMEC/D3 endo-
thelial cells [7], M059K cell apoptosis occurred at
around 20%. Although apoptosis was modest compared
with that in endothelial hCMEC/D3 cells (52%) induced
by heme [7], protection of apoptosis by NRG-1 was sig-
nificant (Fig. 1b). Furthermore, NRG-1 attenuated apop-
tosis of both hCMEC/D3 and M059K cells either
induced by CXCL10 or heme in a dose-dependent man-
ner. In agreement with Lok et al. [27], we used 100 ng/
ml of NRG-1 in the following experiments because at
this concentration more than 50% of apoptotic cells
were rescued (Fig. 1a, b). We next conducted a dose
response assay with heme ranging from 10 to 60 μM to
assess protection of NRG-1 against heme-induced apop-
tosis. Both hCMEC/D3 and M059K cells were treated
with 10 to 60 μM of heme along with 100 ng/ml NRG-1
for 24 h followed by measurement of cell viability using
MTT assay. NRG-1 attenuated 20–30% of heme-induced
hCMEC/D3 cell death at each heme concentration (Fig.
1c). Similar observations were made when neuroglial
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M059K cells were treated with different doses of heme,
reducing 8 to 20.6% cell death in the presence of
100 ng/ml of NRG-1 for 24 h (Fig. 1d). Figure 1e indi-
cated that hCMEC/D3 used in the experiments express
the characteristic endothelial cell marker von Willebrand
factor VIII (VWF).
NRG-1 attenuates heme-induced tight junction disruption
in an in vitro BBB model
The BBB functions as a barrier to restrict movement of
potentially toxic substances from the circulation to the
central nervous system [28]. It has been demonstrated
that a polymerized cell-free Hb (HbG) (extracellular Hb)
triggers BBB disruption and oxidative stress in a guinea
pig exchange transfusion model [29]. However, it is un-
clear whether hemoglobin-derived heme, which induces
cytotoxic oxidative stress, alters the permeability/integ-
rity of BBB and/or disrupts intercellular tight junctions
(TJs) of endothelia in addition to promoting endothelial
cell and astrocyte apoptosis. We treated hCMEC/D3
cells grown in a monolayer with 30 μM heme and NRG-
1 (100 ng/ml) followed by staining with antibodies
Fig. 1 NRG-1 protects against CXCL10, heme-induced astrocytes, and endothelial cell apoptosis. Human brain microvascular endothelial cells (hCMEC/
D3) and human neuroglial cells/astrocytes (M059 K) were treated with increasing doses of NRG-1 followed by CXCL10 or heme treatment, respectively,
for 24 h. Apoptosis and cell proliferation were measured by TUNEL or MTT assay accordingly. a CXCL10 induces apoptosis in hCMEC/D3 and M059K
cells in a dose-dependent manner. Addition of NRG-1 ranging from 50 to 250 ng/ml attenuated apoptosis in hCMEC/D3 and M059K cells. b 30 μM
of heme-induced apoptosis in hCMEC/D3 and M059K cells around 52 and 20%, respectively. NRG-1 protected against heme-induced apoptosis of
hCMEC/D3 and M059K cells in a dose-dependent manner. c. Treatment of hCMEC/D3 cells with heme at the concentration from 10 to 60 μM for 24 h
induced 20–30% apoptosis in a dose-dependent manner, and cell apoptosis was attenuated when cells were pre-incubated with 100 ng/ml of NRG-1
(*p < 0.05). d Treatment of M059K cells with heme at concentration from 10 to 60 μM for 24 h induced 8.0–20.6% cell death in a dose-dependent
manner, and cell apoptosis was attenuated when cells were pre-incubated with 100 ng/ml of NRG-1 (*p < 0.05). e The hCMEC/D3 cells expressed vWF,
an endothelial cell marker
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against tight junction proteins claudin5, ZO-1, and
occludin. Claudin5 was located on cell membranes (ar-
rows) while the membrane-bound staining disappeared
after the cells were treated with 30 μM heme for 24 h
(Fig. 2a, b). NRG-1 treatment prevented reduction of
membrane-bound claudin5 by heme (Fig. 2c, d). The
fluorescence intensity of claudin5 signals in hCMEC/D3
cells treated with heme, NRG-1, heme/NRG-1, and cor-
responding control were quantitatively analyzed in 500
cells per treatment using an ImageJ software program
(Version 1.51j8, National Institutes of Health (NIH)).
The average relative intensity of cells was 177.44 ± 16.45
in controls. The average immunofluorescence intensity
associated with claudin5 antibody of cells treated with
heme was 129.33 ± 13.16 (p < 0.05). In contrast, the aver-
age immunofluorescence intensity with claudin5 anti-
body increased to 165.23 ± 17.11 when NRG-1 was
added to heme-treated cells (p < 0.05, Fig. 2e). Similar
observations were obtained with ZO-1 (Fig. 2f–i) as
those obtained with claudin5. The average relative inten-
sity of ZO-1 of heme-treated cells decreased to 96.99 ±
10.35 as compared to controls 136.16 ± 13.00 (p < 0.05,
Fig. 2 NRG-1 attenuates heme-induced damage of human brain microvascular endothelial cells (hCMEC/D3). a–d A monolayer of hCMEC/D3 cells
were grown confluently and treated with 30 μM heme and NRG-1100 ng/ml followed by staining with anti-claudin5 antibody against tight
junction protein claudin5. Claudin5 was expressed on cell membranes (arrows) which disappeared after the cells were treated with 30 μM heme
for 24 h. NRG-1 treatment inhibited the disruption of heme-induced Claudin5 membrane expression. e Claudin5 antibody immunoreactive signals
in hCMEC/D3 cells were quantitatively analyzed under each treatment as indicated. The fluorescence intensity (red) of cells was measured in 500
cells per treatment using an ImageJ software program (Version 1.51j8, National Institutes of Health (NIH)). The average relative intensity of cells
associated with claudin5 antibody was 177.44 ± 16.45 in controls. Heme treatment reduced the average intensity to 129.33 ± 13.16 (p < 0.05). In
contrast, NRG-1 treatment increased the average fluorescence intensity back to 165.23 ± 17.11 (p < 0.05). The asterisks indicate significant difference
with a p value of 0.05 as determined with Student’s paired t test. f–i hCMEC/D3 cells were grown in monolayer treated with 30 μM heme and 100 ng/
ml NRG-1 and stained with anti ZO-1 antibody against tight junction protein ZO-1. ZO-1 is expressed on cell membranes (arrows) and disappeared
after cells were treated with 30 μM heme for 24 h. NRG-1 treatment inhibited disruption of heme-induced ZO-1 membrane expression. j Quantitation
of ZO-1 staining from samples of hCMEC/D3 cells treated with heme, NRG-1, combination of heme and NRG-1, and corresponding control. Total
immunofluorescence intensity with ZO-1 antibody (red) was determined with ImageJ software program, and the average values for the indicated
number of cells (n = 500) examined were as shown. Briefly, the average relative intensity of ZO-1 of heme-treated cells decreased to 96.99 ± 10.35 as
compared to controls 136.16 ± 13.00 (p < 0.05). The average immunofluorescence intensity with ZO-1 antibody increased to 125.45 ± 11.78 when
NRG-1 was added to heme-treated cells (p < 0.05). The asterisks indicate significant difference with a p value of 0.05 as determined with Student’s
paired t test. k–n hCMEC/D3 cells were grown in monolayer treated with 30 μM of heme and NRG-1100 ng/ml and thereafter stained with anti-
occludin antibody. Occludin is expressed on cell membranes (arrows) and disappeared after cells were treated with 30 μM heme for 24 h. NRG-1
treatment prevented the disruption of heme-induced occludin expression. o The average relative intensity of occludin in heme-treated cells decreased
to 88.04 ± 9.24 compared to controls 137.34 ± 14.23 (p < 0.05), while the average immunofluorescence intensity increased to 136.00 ± 15.00 when
NRG-1 was added to heme-treated cells (p < 0.05). The asterisks indicate significant difference with a p value of 0.05 as determined with Student’s
paired t test
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Fig. 2j). The average immunofluorescence intensity with
ZO-1 antibody increased to 125.45 ± 11.78 when NRG-1
was added to heme-treated cells (p < 0.05, Fig. 2j). The
expression of occludin (Fig. 2k–n) showed the same pat-
tern as that of claudin5 and ZO-1. The average relative
intensity of occludin in heme-treated cells decreased to
88.04 ± 9.24 compared to controls 137.34 ± 14.23 (p < 0.
05). The average immunofluorescence intensity of occlu-
din antibody increased to 144.10 ± 15.00 when NRG-1
was added to heme-treated cells (p < 0.05, Fig. 2o). These
results suggest that NRG-1 protects against heme-
induced damage of tight junction integrity in the BBB.
To further examine the role of NRG-1 on the in vivo
BBB conditions, we employed a two-dimensional (2D) in
vitro BBB model to promote a phenotype that more
closely mimicks in vivo physiological or pathological
conditions as previously described [28, 30–33]. To en-
able better attachment of endothelial cells to support
surfaces for immunofluorescent staining, the protocol
was slightly modified. In our 2D transwell co-culture
system, the monolayer of hCMEC/D3 was placed in the
lower surface of the filter (brain side), with the upper
chamber (blood side) containing neuroglial cell cultures
from human A172 glioma (Fig. 3a–d). Treatment was
initiated after 7 days of co-culture between the two cell
types. The endothelial cells were allowed to acquire the
appropriate BBB phenotype needed for the assay and to
produce cytokines or key soluble substances [34]. This
syngeneic co-culture model of endothelial and neur-
oglia/astrocyte cells increases tight junction resistance
between the endothelial cells compared to endothelial
cells grown alone (one-dimensional). Expression of tight
junction protein markers were assayed by staining with
antibodies against tight junction proteins such as clau-
din5, ZO-1, and occludin. Claudin 5 was expressed on
cell membranes (arrows) in co-cultured hCMEC/D3
with human neuroglia as observed with hCMEC/D3
monolayer culture. The membrane-bound expression
was disrupted and/or disappeared, while cytoplasm stained
more densely after cells were treated with 30 μM heme for
24 h (Fig. 3a, b, arrows). NRG-1 attenuated the disruption
of claudin5 expression induced by heme (Fig. 3c, d). Quan-
titative analysis of immunoreactive signals of claudin5 anti-
body in hCMEC/D3 cells indicate decreased staining from
pronounced (401.80 ± 39.00) in control to moderate (303.
21 ± 32.67) after treatment with heme (n = 500, p < 0.05),
while staining for claudin5 proteins in cells treated with
NRG-1 (385.00 ± 39.97, p < 0.05, Fig. 3e) increased signifi-
cantly. Similar results were observed for ZO-1(Fig. 3f–j).
The average immunofluorescence intensity for ZO-1 de-
creased to moderate levels (114.69 ± 11.60) in heme-treated
cells when compared to control (192.17 ± 20.01, n = 500, p
< 0.05), while the intensity of staining returned to pro-
nounced levels (187.46 ± 16.78) when cells were treated
with NRG-1 (p < 0.05, Fig. 3j). The expression pattern of
occludin was similar to that of claudin5 (Fig. 3k–o). The
average relative intensity of occludin in cells treated with
heme decreased to 170.11 ± 15.89 as compared to that in
control 303.34 ± 28.98 (n = 500, p < 0.05). The average im-
munofluorescence intensity with occludin antibody in-
creased to 489.24 ± 47.92 when NRG-1 was added to the
cells treated with heme (p < 0.05, Fig. 3o).
Effects of NRG-1 on permeability of endothelial cells
BBB function can be examined by assessing permeability
of confluent endothelial cells to sodium fluorescein (SF;
MW = 376 kDa) [28]. Heme-induced endothelial cell
permeability was assessed by growing hCMEC/D3 cells
to confluence on the inner surface of gelatin-coated
transwell inserts followed by incubation of cells with
30 μM heme, 10 ng/ml IL-1β, 1 μg/ml lipopolysacchar-
ide (LPS), and 100 ng/ml NRG-1 for 24 h as indicated,
respectively, while LPS and IL-1β served as positive con-
trols. Permeability was measured by adding 10 μM so-
dium fluorescein to the upper chamber as previously
described [35] (Fig. 4). Incubation with heme, LPS, and
IL-1β resulted in increased permeability of the endothe-
lial monolayer by 1.93-fold, 1.92-fold, and 2.33-fold, re-
spectively. Addition of NRG-1 during incubation of the
cells reduced endothelial permeability by 1.32-fold, 1.50-
fold, and 1.8-fold, respectively (Fig. 4).
Regulation of brain NRG-1 levels following ECM
Neuregulin-1 gene encodes various isoforms which are
generated by transcription from six promoters and alter-
native splicing of primary transcripts [19, 36]. NRG-1
variants vary with four distinct domains: (1) the N-
terminal domain, (2) the EGF-like domain, (3) the juxta-
membrane domain, and (4) the C-terminal domain [37].
All functional variants contain EGF-like domain essen-
tial for interaction with ErbB receptors [37]. The EGF
domain differs in the inclusion of exon A or B, which is
referred as to α isoforms if it is derived from exon A or
β isoforms derived from exon B [36, 37]. β isoforms have
higher affinity for the receptor and tend to produce a
more robust, long-term signal as compared to α iso-
forms [36, 37]. NRG-1 is mainly expressed in neurons
and Schwann cells of the nervous system in human [38]
and mouse [19], in human/mouse endothelial cells [27,
39] and cardiomyocytes [40], and in human cornea epi-
thelial and stroma cells [37]. They play complicated roles
in the development of the nervous and the cardiovascu-
lar systems. NRG-1 is initially synthesized as a trans-
membrane protein; however, it does not reach the cell
surface and is expressed as soluble or cytosolic proteins
[18] or nuclear protein [41] without a transmembrane
domain. We assessed total NRG-1 protein expression
level in serum by enzyme-linked immunosorbent assay
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(ELISA) of ECM (n = 5/group). Circulating blood NRG-1
level significantly increased in mice 6 days post infection
and declined to a level below that of uninfected mice
(controls) 8 days post infection when fatal brain damage
occurred (Fig. 5a). This decline in NRG-1 suggests inad-
equate protection of endogenous serum NRG-1 against
severe late-stage factors of ECM indicating that low
plasma NRG-1 level correlates with clinical severity of
ECM. To determine the relationship between tissue
NRG-1 expression especially in brain tissue and malaria
infection, total RNA, and whole-cell protein lysate were
extracted from ECM mice at different time points. Infec-
tion of C57BL/6 mice with Plasmodium berghei ANKA
(PbA) upregulated NRG-1 mRNA in the brain cortex
(Fig. 5b) suggesting that NRG-1 expression may be pro-
tective against PbA-induced damage in the brain.
Fig. 3 NRG-1 attenuates heme-induced damage of BBB in an in vitro BBB model consisting of human brain microvascular endothelial cells (hCMEC/
D3) and neuroglial cells/astrocytes of human A172 glioma cells. a–d When hCMEC/D3 was co-cultured with human neuroglial cells/ astrocytes
(human A172 glioma), Claudin 5 was expressed on cell membranes (arrows) and disappeared following treatment with 30 μM heme for 24 h.
Additionally, heme reduced Claudin5 expression while NRG-1 attenuated heme-induced reduction in claudin5 expression. e Quantitation of
claudin5 staining of hCMEC/D3 co-cultured with A172 astrocytes by different treatment as indicated. Total immunofluorescence intensity with
claudin5 antibody (red) was determined with ImageJ software program, and the average value for the indicated number of cells examined
(n = 500) is shown. Quantitative analysis of immunoreactive signals of claudin5 antibody in hCMEC/D3 cells indicated decreased staining from
pronounced (401.80 ± 39.00) in control to moderate (303.21 ± 32.67) after treatment with heme (n = 500, p < 0.05), while staining for claudin5
proteins in cells treated with NRG-1 increased significantly (385.00 ± 39.97, p < 0.05). The asterisks indicate significant difference with a p value of
0.05 as determined with Student’s paired t test. f–i When hCMEC/D3 was co-cultured with human neuroglial cells/ astrocytes (A172 glioma), tight
junction protein marker ZO-1 was expressed on cell membranes (arrows). The membranous staining was disrupted and cytoplasmic staining was
more dense after cells were treated with 30 μM heme for 24 h. In addition, heme reduced ZO-1 expression while NRG-1 increased ZO-1
expression reduced by heme. j Quantitation of ZO-1 staining of hCMEC/D3 co-cultured with A172 astrocytes by different treatment as indicated.
Total immunofluorescence intensity with ZO-1antibody (red) was determined with ImageJ software program, the average value for the indicated
number of cells examined (n = 500) is shown. Briefly, the average immunofluorescence intensity for ZO-1decreased to moderate 114.69 ± 11.60 in
heme-treated cells as compared to control (192.17 ± 20.01, p < 0.05), while the intensity of this staining returned to pronounced levels (187.46 ±
16.78) when the cells were treated with NRG-1 (p < 0.05). The asterisks indicate significant difference with a p value of 0.05 as determined with
Student’s paired t test. k–n When hCMEC/D3 was co-cultured with human neuroglial cells/astrocytes from human A172 glioma, tight junction
protein marker occludin was expressed on cell membranes (arrows). The membrane-bound expression disappeared after cells were treated with
30 μM heme for 24 h. In addition, heme reduced occludin expression, and NRG-1 increased occludin expression reduced by heme. o Quantitation
of occludin staining in hCMEC/D3 cells treated with heme, NRG-1, combination of heme and NRG-1, and corresponding control. Total immunofluorescence
intensity with occludin antibody (red) was determined with ImageJ software program, and the average value for the indicated number of cells examined
(n= 500) is shown. The average relative intensity of occludin in cells treated with heme decreased to 170.11 ± 15.89 as compared to control 303.34 ± 28.98
(n = 500, p < 0.05). The average immunofluorescence intensity with occludin antibody increased to 350.00 ± 47.92 when NRG-1 was added to the cells
treated with heme (p < 0.05). Together, these results suggest that NRG-1 protects against heme-induced damage of brain vascular endothelial cells in
in vitro BBB model
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Consistent with the levels of mRNA detected by real-
time reverse transcription polymerase chain reaction
(qRT-PCR) assay (Fig. 5b), total NRG-1 protein levels in
the cortex tested by Western blot were significantly ele-
vated in PbA-infected C57 BL/6 mice (Fig. 5c, d).
NRG-1 attenuated ECM mortality-associated ErbB4/STAT3/
AKT signaling
Next, we investigated whether exogenously infused re-
combinant human NRG1-beta1 (rhNRG-1) containing
EGF-like domain into ECM mice activates the NRG-1/
ErbB4 signaling pathway, which is functionally active in
ischemia/reperfusion-induced injuries [17]. Real-time
quantitative PCR results showed that PbA infection did
not change ErbB4 expression in the cortex (Fig. 6a).
Whole extracts of mouse cortex tissues were analyzed
by Western blots with antibody to the phosphotyrosine
residue Tyr1284 within ErbB4 and total ErbB4 antibody.
Extracts of cortex showed gradually decreased ErbB4
phosphorylation at Tyr 1284 after 2 days of PbA infec-
tion and was hardly detectable by day 12 (upper panel of
Fig. 6b). Protein extracts from pooled hippocampus of
mice were also probed with antibodies to phosphory-
lated ErbB4 (Tyr1284) and total ErbB4. The pattern of
pErbB4 protein expression from pooled hippocampus
tissues was similar to those in the cortex (lower panel of
Fig. 6b). Phosphorylated ErbB4 decreased when mice
were infected with P. berghei ANKA. Consistent with
Fig. 4 NRG-1 reduces heme-induced endothelial cell permeability.
hCMEC/D3 cells were grown on the inner surface of gelatin-coated
transwell inserts, then incubated with 30 μM heme, 10 ng/ml IL-1β,
1 μg/ml lipopolysaccharides (LPS), and 100 ng/ml NRG-1 as indicated
for 24 h. Permeability was measured by adding 10 μM sodium
fluorescein to the upper chamber. After incubation for 0.5 h, the
sample from the lower compartment was collected and 100 μl of
sample was measured for fluorescence at excitation 485 nm and
emission 535 nm. Incubation with heme, LPS, and IL-1β resulted in
increased permeability of the endothelial monolayer by 1.93-fold,
1.92-fold, and 2.33-fold, respectively. The presence of NRG-1 during
the incubation period reduced endothelial permeability down to
1.32-fold, 1.50-fold, and 1.8-fold, respectively
Fig. 5 Circulating NRG-1 levels decrease while expression levels of NRG-1 in brain tissue increase in ECM mice. a Peripheral circulating blood in mice
(n = 5/group) was assessed for total NRG-1 protein expression in serum by ELISA. Peripheral blood level of NRG-1 is significantly increased 6 days
post infection in mice, but declined to a level below that of uninfected mice 8 days post infection (stage when mice begin to develop fatal brain
damage). b Infection of C57BL/6 WT mice with PbA upregulated NRG-1 mRNA in brain tissue. c NRG-1 protein levels tested by Western blot
analysis in the cortex were significantly increased in PbA-infected WT of C57 BL/6 mice. d A densitometeric analysis of bands on Western blot
was performed with the ImageQuant program. The data are presented as fold stimulation relative to appropriate controls and are the mean ± SE
of duplicated samples performed in three independent experiments
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total mRNA expression, levels of total ErbB4 protein did
not change in either the cortex or hippocampus. Im-
munofluorescence (IFC) results confirmed the findings
of Western blot analysis whereby total ErbB4 protein
remained unchanged 12 days after infection (Fig. 6c,
panels a, b). In addition, IFC data showed that ErbB4
co-localized with the neuronal marker-NeuN (Fig. 6d,
panels a–c), but not with microglial cell marker Iba1
(Fig. 6d, panels d–f ), or astrocyte marker glial fibrillary
acidic protein (GFAP) (Fig. 6d, panels g–i). Remarkably,
exogenous NRG-1 (at both low (5 μg/kg) and high
(25 μg/kg) doses) in combination with/without arte-
mether (ARM) treatment partially restored expression of
pErbB4 in both cortex (Fig. 7a) and pooled hippocampus
tissues (Fig. 7c). pErbB4 levels increased in PbA-infected
mice treated with NRG-1 and ARM individually, while
there was robust increase in animals treated with both
NRG-1 and ARM (NRG-1+ARM or NRG-1/ARM repre-
sents combination of NRG-1 and ARM), particularly in
pooled samples prepared from hippocampal tissues (Fig.
7c). These data suggest that the ErbB4 receptor is acti-
vated through phosphorylation after the treatment with
Fig. 6 Phosphorylated ErbB4 (pErbB4) levels decrease in ECM mice. a Total mRNA level of ErbB4 in brain cortex was unchanged during infection
with PbA. b Protein extracts from the cortex and hippocampus of mice were probed with antibodies against phosphorylated ErbB4 (Tyr1284) and
total ErbB4. The data represent one of three independent experiments with similar results. Beneath the Western blot is a densitometric analysis of
bands assessed with the ImageQuant program. The data are expressed as fold stimulation relative to appropriate controls and are the mean ± SE
of duplicated samples performed in three independent experiments. Total protein level of ErbB4 in the brain cortex was unchanged during ECM,
whereas phosphorylated ErbB4 (pErbB4) gradually decreased from day 2 and was hardly detectable at day 12. Expression pattern of pErbB4 in
hippocampus was similar to that observed in cortex (*p < 0.05, **p < 0.01, compared to uninfected (UN) sample at D2). c Immunofluorescence
(IFC) results confirmed the Western blot data, in which total ErbB4 protein was unchanged even 12 days after infection (panels a, b). d IFC data
showed that ErbB4 co-localized with neuronal marker-NeuN (panels a–c), but not with microglial cell marker-Iba1 (panels d–f), or astrocyte
marker-GFAP (panels g–i)
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NRG-1 infusion. We further examined the putative down-
stream pathways activated by NRG-1/ErbB4. Our interest
in signal transducer and activation of transcription 3
(STAT3) and AKT signaling pathways derives from the
reported importance of STAT3 in the pathogenesis of
cerebral malaria [7, 42] while AKT activation is a typical
downstream signal molecule for NRG-1/ErbB4 [17].
Activated STAT3 induced by Plasmodium infection was
inhibited by treatment with NRG-1 and/or ARM as ex-
pected (Fig. 7b, d). In addition, pAKT is upregulated both
in brain cortex (Fig. 7b) and hippocampus (Fig. 7d) of
PbA-infected mice when treated with NRG-1 and/or
ARM compared to untreated control. These results
strongly indicate that NRG-1 plays an important role in
attenuation of mortality associated with ECM through
ErbB4/STAT3/AKT signaling. We also examined whether
this mechanism applied to in vitro cell culture systems. To
this end, hCMEC/D3 cells were grown and treated with
30 μM of heme with or without 100 ng/ml of NRG-1.
Whole cell lysates were isolated under each condition as
indicated in Fig. 8, transferred to membranes and probed
with pSTAT3/tSTAT3 and pAKT/tAKT antibodies. Con-
sistent with the observation made in our in vivo study the
results show that NRG-1 reduced heme-induced STAT3
activation and increases heme-reduced ErbB4 and AKT
activation (Fig. 8).
Discussion
NRG-1 is a member of a family of growth factors which
are very important in the development of the heart,
Fig. 7 NRG-1 attenuates mortality associated with ECM through ErbB4/STAT3/AKT signaling. Protein lysates from different brain regions including the
cortex and hippocampus of ECM mice subjected to exogenously infused NRG-1 were probed with antibodies against phosphorylated STAT3, total
STAT3, phosphorylated ErbB4 (Tyr1284), total ErbB4 (tErbB4), phosphorylated AKT, and total AKT as indicated. a pErbB4 levels increased in PbA-
infected mice treated with NRG-1 and ARM individually in brain cortex. b Exogenous treatment of NRG-1 and/or ARM inhibited activation of
STAT3 and increased activation of pAKT in the brain cortex. Beneath the Western blot is the densitometric analysis of the bands performed with
the ImageQuant program. The data are expressed as the fold stimulation relative to appropriate controls and are the mean ± SE of duplicated
samples performed in three independent experiments. (*p < 0.05, **p < 0.01, compared to infected sample at first column). c pErbB4 levels increased in
PbA-infected mice treated with NRG-1 and ARM individually, while there was a robust increase when treated with both NRG-1 and ARM (NRG-1/ARM)
in pooled samples prepared from hippocampal tissues. d Exogenous treatment of NRG-1 and/or ARM inhibited activation of STAT3 and increased
activation of pAKT in brain hippocampus. Beneath the Western blot is the densitometric analysis of the bands performed with the ImageQuant
program. The data are expressed as the fold stimulation relative to appropriate controls and are the mean ± SE of duplicated samples performed in
three independent experiments. (*p < 0.05, **p < 0.01, compared to infected sample at first column). All the data represent one of three independent
experiments with similar results
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mammary glands, and the nervous system [10]. In agree-
ment with the known capacity of NRG-1 to attenuate
neuronal apoptosis [17], we demonstrate that NRG-1
protects heme-induced endothelial and neuroglial cell
death/apoptosis (Fig. 1). NRG-1 has been shown to be
neuroprotective against CNS injury. For instance, in an
in vivo experimental trauma model, NRG-1 improved
endothelial biological features and reduced BBB perme-
ability and then consequently strengthened BBB struc-
ture [43]. In our in vitro BBB model, NRG-1 protected
against heme-induced disruption of BBB integrity by
strengthening tight junction proteins (Figs. 2 and 3).
NRG-1, a growth factor distributes and accumulates in
many regions of the brain, including frontal cortex, stri-
atum, and ventral midbrain containing the substantia
nigra after systemic application [44]. It targets the en-
tire neurovascular units/cell types such as neuronal
cells, oligodendrocytes, endothelial cells, and macro-
phages to accomplish its potent neuroprotective roles.
NRG-1 protects against neuronal death/apoptosis in-
duced by oxygen-glucose deprivation (OGD) [45–47],
ischemic reperfusion [48], and deep hypothermic circu-
latory arrest [17]. It prevents apoptosis of oligodendro-
cyte progenitor cells caused by OGD [49] and involved
in the repair process once the perinatal brain white matter
is damaged [38]. It inhibits inflammatory responses either
by downregulating pro-inflammatory/inflammatory gene
expression in macrophages and resident microglia or
hampering macrophage infiltration [45]. Thus, NRG-1 has
the potential to be used as a novel therapeutic for treat-
ment of CM since its pathway regulates endothelial cell
activities and reduces BBB permeability.
NRG-1 engages the ErbB receptor tyrosine kinases
through its EGF-like domain, activation of ErbB
receptors impacts cell proliferation, migration, differenti-
ation, and apoptosis in a variety of cell types. The NRG-
1/ErbB axis initiates and promotes Schwann cell devel-
opment and myelination through mobilization of Ca2+,
activation of nuclear factor of activated T cells (NFAT),
activation of kinases such as Ca2+-dependent protein
kinase C (PKC), ras/extracellular signal regulated kinase
½ (Erk1/2), and phophatidylinositol-3-kinase (PI3K/
AKT) [50, 51]. Among these pathways, ErbB4-mediated
PI3K/AKT signaling pathway is especially crucial against
apoptosis [49]. However, the mechanism by which NRG-
1/ErbB interaction protects against cerebral malaria
pathogenesis is unknown. For instance, it is unclear how
NRG-1 activates its ErbB receptor to protect against
cerebral malaria pathogenesis. The extent to which this
protection occurs in any specific tissues and regions of
the brain remains largely unknown. In the present study,
we determined that the ErbB4 protein is inactivated
through dephosphorylation in the cortex and hippocam-
pus of mice with advanced stages of ECM (Fig. 6) indicat-
ing a diffuse distribution of brain lesions. In contrast,
exogenous NRG-1 infusion increases phosphorylated
ErbB4 levels in the cortex and hippocampus of infected
mice, which subsequently reduces STAT3 activation—a
typical pathogenic pathway in CM [7, 42] and increases
AKT activation (Fig. 7). Our findings are consistent with
Lok’s report which showed that NRG-1 increases pAKT
to enhance survival of endothelial cells in in vitro cell cul-
tures [27]. Gene microarray data analysis revealed that
NRG-1 downregulated hemeoxygenase-1 (HO-1), a heme
scavenger [45], suggesting that NRG-1 may interrupt
heme-induced pathogenic signaling pathways in brain
endothelial cells. Our findings support the observation
that NRG-1 reduces heme-induced STAT3 activation
Fig. 8 NRG-1 inhibits STAT3 activation and ErbB4/AKT inactivation in vitro. hCMEC/D3 cells were treated with NRG-1 for 30 min followed by stimulation
with 30 μM heme for 24 h. Lysates were extracted and stained with antibodies against STAT3, ErbB4, and AKT as indicated by Western
blot. a NRG-1 inhibited heme-induced STAT3 activation, increased heme-reduced ErbB4/AKT activation. b A densitometric analysis of bands
on blots was performed with the Image Quant program (Bio-Rad). The data are expressed as the fold stimulation relative to appropriate controls and
are the mean ± SE of duplicated samples performed in three independent experiments. (*p < 0.05)
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while increasing ErbB4/AKT activation when human
endothelial cells are co-treated with heme and NRG-1 in
cell culture (Fig. 8).
Although NRG-1 is initially synthesized as transmem-
brane protein, NRG-1 is cleaved by proteases and the
soluble form of NRG-1 impacts significantly the function
of the nervous system [18]. Plasma soluble NRG-1 has
been detected as a diagnostic biomarker for Alzheimer’s
disease [52]. The cause of increased expression of NRG-
1 including blood NRG-1 levels after PbA infection is
not clear. We speculate that STAT3 could be one of reg-
ulators since the promoter of NRG-1 contains a number
of STAT3 binding sites. Our in vitro data strongly indi-
cate that increased NRG-1 level reduced damage to the
blood brain barrier. So far, no evidence indicates any
functional differences between increased NRG-1 during
infection and infused NRG-1. However, the bioavailabil-
ity of infused NRG-1 is very low in circulation; Ford’s
group (co-author) reported that the half-life of NRG-1
was short, the plasma t ½ was about 8 min after exogen-
ous intraarterial injection of NRG-1, while it was present
in brains of animals at 20 min post administration and
remained at a constant level for up to 4 h post injection
[53].
Our data demonstrates that circulating NRG-1 levels
correlate with clinical severity of ECM. Interestingly, a
previous report by Hama et al. in 2015 [21] indicated
that NRG-1 level in plasma did correlate with clinical se-
verity of Parkinson’s disease. Surprisingly, infusion of
higher doses of NRG-1 in our study did not produce ex-
ponential effects as expected compared to the optimum
dose of NRG-1 utilized. The reason for this is unclear.
However, Xu et al. [49] found that NRG-1 exerts a dual
function in the myelination of oligodendrocytes. It ap-
pears that excessive stimulation of NRG-1β signaling
may not be beneficial but detrimental for neural func-
tion. Low doses of NRG-1 stimulates myelination in
vitro [54] while overexpression of NRG-1 in myelinating
Schwann cells caused hind limb paralysis, which indi-
cates that over-activation of NRG-1 signaling may gener-
ate aberrant Schwann cell activity [49]. We are aware
that the neuronal cell scenario is different from that of
endothelial cells. However, both cell types are indirectly
relevant to HCM and ECM and may explain why higher
doses of NRG-1 may fail to produce exponential effects
as observed for low doses. Taken together, our results in-
dicate that judicious augmentation of NRG-1 during
anti-malaria therapy against CM may be an effective
therapeutic approach to increase effectiveness of current
anti-malaria therapy against CM.
Conclusion
Neuregulin-1 (NRG-1) is encoded by the gene NRG1, a
member of a family of polypeptide growth factors, which
is essential for the normal development of the nervous
system and the heart. Following our first report of its
protective role in experimental cerebral malaria (ECM),
we further examined how NRG-1 mechanistically atten-
uates ECM pathogenesis and reduces mortality. Our re-
sults indicate that NRG-1 protects against cell death/
apoptosis of human brain microvascular endothelial and
neuroglial cells and prevents BBB disruption. Our results
also demonstrate that NRG-1 attenuated ECM mortality
is associated the activation of ErbB4/AKT and inactiva-
tion of STAT3 signaling pathways.
Methods
Animal study
Infection of mice with P. berghei ANKA was performed
as described previously [26]. Mice were selected and
randomized into treatment groups after diagnosis with
ECM [26] on days 5 to 6 post infection. To determine
the therapeutic benefit of NRG-1 on ECM-associated
brain damage and mortality and to compare NRG-1 with
artemether (ARM) treatment, PbA-infected mice were
treated daily via i.p. injection with 50 μl doses of NRG-1
(5 or 25 μg/kg/day, EGF-like domain, R & D Systems,
Minneapolis, MN, USA) [NP_039250] or artemether
prepared in coconut oil (25 mg/kg/day, Sigma-Aldrich,
St Louis, MO, USA) from days 6 to day 11 post infec-
tion. The mice treated daily with 50 μl saline solution (i.
p.) from days 6 to 11 post infection were used as the
controls. Mice were checked several times daily for mor-
tality and signs of ECM neurological symptoms such as
ataxia, loss of reflex, and hemiplegia. All murine ECM
experiments were terminated 19 days after PbA infection
with animals being euthanized accordingly [26].
Antibodies and reagents
Rabbit antibody against STAT3, phospho-STAT3, rabbit
antibody against AKT, phospho-AKT, anti-NeuN, anti-
Iba1, and anti-glial fibrillary acidic protein (GFAP) were
purchased from Cell Signaling Technology Inc. (Danvers,
MA, USA). Polyclonal antibody to β-actin, lipopolysac-
charide (LPS), and sodium fluorescein were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Rabbit poly-
clonal antibodies against claudin5, ZO-1, and phosphory-
lated ErbB4 (monoclonal) antibody were purchased from
Abcam (Cambridge, MA, USA). Rabbit polyclonal anti-
body against occludin and attachment factor (AF) was
purchased from Invitrogen (Waltham, MA, USA). Rabbit
antibody against VWF was purchased from Dako (Santa
Clara, CA, USA). Anti-ErbB4 (polyclonal) and NRG-1
(polyclonal) antibodies were purchased from Santa Cruz
(Dallas, TX, USA). All secondary antibodies used for
Western blot were purchased from Calbiochem (La Jolla,
CA, USA). Hemin (heme) was purchased from Frontier
Scientific (Logan, UT, USA). Recombinant human
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NRG1β1/HRG1β EGF domain protein (γhNRG-1) and re-
combinant human CXCL10/IP-10 protein were purchased
from R&D systems (Minneapolis, MN). Recombinant hu-
man interleukin-1β (IL-1β) was purchased from Millipore
(Billerica, MA, USA).
Cell culture
The hCMEC/D3 a cell line (Cellutions Biosystems Inc.,
Ontario, Canada) was derived from human temporal
lobe microvessels and were immortalized with hTERT
and SV40 large T antigen. The cells have been exten-
sively characterized for brain endothelial phenotype and
are a model of human blood brain barrier (BBB) func-
tion. hCMEC/D3 cells were cultured at 37 °C with 5%
CO2 in endothelial basal medium-2 (Lonza) supple-
mented with 5% fetal bovine serum (FBS; American
Type Culture Collection (ATCC), Manassas, VA, USA),
growth factors and other supplements including human
recombinant epidermal growth factor (hEGF), hydrocor-
tisone, GA-100 (Gentamicin, Amphotericin-B), human
recombinant vascular endothelial growth factor (VEGF),
recombinant human fibroblast growth factor-b (hFGF-b)
, recombinant long R insulin-like growth factor (R3-IGF-
1), ascorbic acid, heparin, 100 U/ml of streptomycin,
and 100 U/ml of penicillin (Lonza). The cells were
harvested and passaged at about 70–90% confluence as
described previously [6]. The hCMEC/D3 cells (2 × 105
cells/ml) were seeded in 35-mm tissue culture dish and
incubated at 37 °C in 5% CO2 for 24–48 h for future
use. M059K cells purchased from ATCC were cultured
at 37 °C with 5% CO2 in DMEM: K-12 medium.
Measurement of cell viability by MTT assay
The hCMEC/D3 or M059K cells were seeded at 1 × 104
cells in 100 μl of medium per well into 96-well plates
and serum-starved for 24 h, incubating with 100 ng/ml
γhNRG-1 for 30 min, followed by exposing to heme at
30 μM or 0.02 μg/ml CXCL10 for 24 h. MTT assay was
performed in accordance to the manufacturer’s instruc-
tions. Ten microliters of MTT reagent (the ratio of
MTT reagent to medium is 1:10) was added into each
well and incubated in the dark at room temperature for
2 to 4 h. Absorbance at 570 nm was measured using
650 nm as reference filter by a CytoFluorTM 2300 plate
reader and the software CytoFluorTM 2300 v. 3A1
(Millipore Co, Bedford, MA, USA).
Immunofluorescence staining
Cells grown in monolayer cultures were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS),
permeabilized with 0.2% Triton X-100 and blocked with
10% goat serum prior to antibody staining. Specific pri-
mary antibodies were added at 1:100 dilution and incu-
bated at 4 °C overnight. Fluorescent staining was
developed using the FITC or Cy3 fluorescence system
(Sigma-Aldrich, St. Louis, MO, USA). TUNEL assay, in
situ cell death detection kit (TMR red; Boehringer-
Mannheim, Mannheim, Germany) was used. The sec-
tions were incubated with the TUNEL reaction solution
for 60 min at 37 °C in the dark. Cover slips were
mounted onto slides with Vectashield mounting medium
with DAPI (H-1200; Vector Laboratories Inc.). Fluores-
cent images were collected by using a Zeiss laser scan-
ning microscope (LSM) 510 confocal microscope, and
images were captured with LSM software, version 2.3
(Carl Zeiss, Wetzlar, Germany). Apoptotic cells and total
cells were counted in ten randomly chosen microscopic
fields, and the percentage of apoptotic cells was calcu-
lated and compared between the experimental and
control groups.
Enzyme-linked immunosorbent assay (ELISA)
Peripheral blood NRG-1 quantification was assayed by
ELISA (MyBioSource, San Diego, CA, USA). At indi-
cated days after PbA infection, a subset of mice (n = 5/
group) was anesthetized, then 500 μL of peripheral
blood was acquired through cardiac puncture. Blood was
immediately placed in a biopsy tube with EDTA to pre-
vent clotting. Plasma was obtained by centrifuging the
whole blood at 1200 g for 15 min at room temperature.
ELISA was performed on all samples to quantify plasma
levels of mouse NRG-1. The samples were read on a mi-
croplate reader (TECAN) at 450 nm.
Endothelial cell permeability assay
Endothelial cell permeability assay was performed as
previously described [28, 43, 55]. In brief, the hCMEC/
D3 cells were cultured in complete growth media EGM-
2 MV (Lonza, Walkersville, MD, USA). The hCMEC/D3
cells were seeded into the inner surface of attachment
factor (AF)/ collagen-coated transwell inserts (24 mm
diameter, 0.4-μm pore size polyester filter; Corning,
Corning, NY, USA), which were placed in wells of a 6-
well plate with human neuroglial/astrocytes (A172 gli-
oma cells). About 7 days after seeding, when hCMEC/
D3 cells grown on the inner surface of the insert were
confluent (confirmed by testing permeability to media),
the cells were serum starved overnight with EBM media
without growth supplement, then incubated with IL-1β
(10 ng/ml), LPS (1 μg/ml), and heme (30 μM) for 24 h.
Thirty minutes prior to addition of IL-1β, LPS and
heme, NRG1 (100 ng/ml = 12.5 nM), or vehicle (PBS)
was added. After 24 h, media in both upper and lower
chambers were removed and replaced with fresh media.
Permeability was measured by adding 0.1 mg/ml of So-
dium Fluorescein (MW, 376 kDa, Sigma, St. Louis,
MO, USA) to the upper chamber. After incubation
for 0.5 h, the sample from the lower compartment
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was collected and 100 μl of sample was measured for
fluorescence at excitation 485 nm and emission
535 nm. All three independent experiments were
performed in triplicate.
Real-time RT-PCR analysis
Cell pellets were stored in Trizol reagent and homoge-
nized in fresh Trizol. Total RNA was isolated from cells
using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA).
Total RNA was quantified using the Nanodrop N-1000
by Agilent Biosystems (Santa Clara, CA, USA). cDNAs
were synthesized from the isolated RNA using iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Inc.). Re-
verse transcription was performed by using random
hexamers at 25 °C for 5 min, 42 °C for 30 min, and
85 °C for 5 min. Quantitative PCR was performed
using iQ SYBR Green Supermix (Bio-Rad Laborator-
ies, Inc.) in a CFX96 Real-Time PCR System machine
(Bio-Rad Laboratories, Inc.). The data was analyzed
using CFX96 Real-Time PCR System (Bio-Rad La-
boratories, Inc.). Primer sequences for the genes were
described in Table 1.
Western blot
Cells were lysed with lysis buffer (50 mM HEPES,
150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% gly-
cerol, 1% Nonidet P-40, 100 mM NaF, 10 mM sodium
pyrophosphate, 0.2 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, and
10 μg/ml leupeptin). Samples were separated by SDS/
PAGE, and separated proteins were transferred to nitro-
cellulose membranes and identified by immunoblotting.
Primary antibodies were obtained from commercial
sources; these antibodies were diluted at the ratio of 1:
1000 according to the manufacturer’s instruction. Blots
were developed with Supersignal Pico or Femto sub-
strate (Pierce). A densitometric analysis of the bands was
performed with the ImageQuant program (Bio-Rad).
Statistical analysis
Statistically significant differences were determined using
Prism statistical software (Graph Prism 4.03, San Diego,
CA, USA). All data were presented as mean ± SEM of at
least three independent experiments. For data analysis,
unpaired t test or one-way ANOVA with Dunnett’s or
Bonferroni’s post test was applied. All P values resulted
from two-sided statistical tests and statistical significance
was set at *p < 0.05, **p < 0.01, and ***p < 0.001.
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